Additional Study Information: This study is a global multicenter, Phase 2, open-label, PoC study evaluating the efficacy, safety, and tolerability of SAR445088 administered to 3 subpopulations of patients with chronic inflammatory demyelinating polyneuropathy (CIDP): patients who are being treated with SOC therapies defined as intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), or corticosteroids; patients with CIDP who are refractory to SOC; and patients with CIDP who are nave to SOC. Adults 18 years of age at the time of signing the informed consent.